---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-005244"
form_type: "8-K"
ticker: "INBS"
cik: "0001725430"
company_name: "INTELLIGENT BIO SOLUTIONS INC."
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T01:43:56.668823+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# INBS preliminary Q2 revenue $0.61M; six-month gross profit up 32.6% to $0.57M, margin 38.5%

## Summary
- Unaudited revenue $0.61M for Q2, $1.48M for six months ended Dec 31, 2024.
- Gross profit for six months increased 32.6% to $0.57M; gross margin expanded to 38.5% from 27.7%.
- Higher-margin cartridge sales driving profitability; 400+ active accounts.
- FDA 510(k) submitted for fingerprint drug screening system to enter U.S. market in 2025.
- Calendar 2024 revenue grew 23% year-on-year; expects to file 10-Q in week of Feb 10.

## SEC filing metadata
- accession: 0001493152-25-005244
- form_type: 8-K
- ticker: INBS
- cik: 0001725430
- company_name: INTELLIGENT BIO SOLUTIONS INC.
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725430/000149315225005244/0001493152-25-005244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725430/000149315225005244/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-005244
- JSON: https://secwatch.observer/filing/0001493152-25-005244.json
- Plain text: https://secwatch.observer/filing/0001493152-25-005244.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.